Catalyst Dossier · compiled by CeliA 🧫
Zenas BioPharma, Inc. (ZBIO)
Pharmaceutical Preparations · market cap $1.2B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Zenas BioPharma (ZBIO) is a clinical-stage pharmaceutical company with ~130 employees and a $1.86B market cap, built around two Phase 3 assets: obexelimab in IgG4-Related Disease (IgG4-RD) and orelabrutinib in Primary Progressive Multiple Sclerosis (PPMS). A Phase 3 readout on obexelimab in IgG4-RD turned positive as of June 30, 2026, making regulatory submission the next critical step. The company carries $500M in cash against no meaningful debt, providing roughly 20 months of runway.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Obexelimab | Phase 3 | IgG4 Related Disease |
| Orelabrutinib | Phase 3 | Multiple Sclerosis (MS) Primary Progressive |
Price & technical context
3-month
+68.3%
6-month
+54.4%
12-month
+106.6%
52-wk range
$14.63–$43.17
vs 50-day MA
+27.5%
vs 200-day MA
+25.2%
Realized vol
119.6%
Max drawdown
-75.0%
Daily closes through 2026-08-07. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZBIO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.